Ebola Virus Disease
Also known as: Ebola Hemorrhagic Fever / Hemorrhagic Fever, Ebola / Ebola Virus Infection / Ebola Disease / Ebola Virus Disease, Ebola Virus Infection, Ebola / Ebola Viral Disease / Ebolavirus Disease / Ebola virus disease (disorder) / Ebola haemorrhagic fever
Drug | Drug Name | Drug Description |
---|---|---|
DB16385 | Ansuvimab | A fully human monoclonal IgG1 antibody directed against the GP1,2 surface protein of Zaire ebolavirus that is an effective treatment for Ebola virus disease. |
DB15898 | Atoltivimab | Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. |
DB15595 | Ebola Zaire vaccine (live, attenuated) | A vaccine used in the prophylaxis of Ebola virus disease caused by the species of Zaire ebolaviruses. |
DB15899 | Maftivimab | Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. |
DB15483 | Modified vaccinia ankara | A live, non-replicating orthopoxvirus vaccine used to prevent smallpox, monkeypox, and other diseases caused by vaccinia virus. |
DB15900 | Odesivimab | Part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB16385 | Ansuvimab | Envelope glycoprotein | target |
DB15898 | Atoltivimab | Envelope glycoprotein | target |
DB15899 | Maftivimab | Envelope glycoprotein | target |
DB15900 | Odesivimab | Envelope glycoprotein | target |